Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update
Editas Medicine, a prominent genome editing company, will host a conference call and webcast on May 4, 2022, at 8:00 a.m. ET to discuss its first-quarter 2022 results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine, a prominent genome editing company, will host a conference call and webcast on May 4, 2022, at 8:00 a.m. ET to discuss its first-quarter 2022 results and provide a corporate update. U.S. participants can dial 877-407-0989, while international callers should use 201-389-0921, approximately five minutes before the call. A live webcast and replay will be available on the Editas Medicine website. The company specializes in developing CRISPR-based genomic medicines aimed at treating serious diseases globally.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was -2.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.
To access the conference call:
- U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.
- Participants should ask to be connected to the Editas Medicine earnings conference call.
A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.